Prescription medicine
Eletriptan Brand names: Relpax
Eletriptan (Relpax) is a prescription medicine with an FDA approval on record since 2002. FDA's NDC Directory lists it from 10 generic labelers, and pharmacies paid $1.75 per eletriptan hbr 40 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the eletriptan FDA label on DailyMed (effective November 27, 2024, Teva Pharmaceuticals USA, Inc.); the NDA 21016 record on Drugs@FDA; every eletriptan label on DailyMed.
Highlights of the record
FDA label of November 27, 2024; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageEletriptan hydrobromide tablets are indicated for the acute treatment of migraine with or without aura in adults.
Forms and strengths
- 20 mg
- 40 mg
Film-coated tablet; tablet.
On the market
- Earliest approval on file
- December 26, 2002 Relpax, Upjohn; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 9 first June 16, 2017; 7 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 11 of which 10 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $1.75 per tablet Eletriptan hbr 40 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 1 since 2021 0 Class I among all firms' recalls; latest March 15, 2021
- FAERS reports
- 6,996 through July 30, 2026
What is eletriptan used for?
From the label: indications and usageEletriptan hydrobromide tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use: Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with eletriptan hydrobromide tablets, reconsider the diagnosis of migraine before eletriptan hydrobromide tablets are administered to treat any subsequent attacks. Eletriptan hydrobromide tablets are not intended for the prevention of migraine attacks. Safety and effectiveness of eletriptan hydrobromide tablets have not been established for cluster headache. […]
Conditions named in the indications of eletriptan's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Serotonin-1b and Serotonin-1d Receptor Agonist.
Source: FDA drug label (Eletriptan Hydrobromide), Teva Pharmaceuticals USA, Inc., effective November 27, 2024 (SPL set 62dc12ce-4f19-41c6-9593-3cae29f04af1), via openFDA; the full label on DailyMed
What does the patient leaflet for eletriptan say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about eletriptan hydrobromide tablets?Eletriptan hydrobromide tablets can cause serious side effects, including: Heart attack and other heart problems. Heart problems may lead to death. Stop taking eletriptan hydrobromide tablets and get emergency medical help right away if you have any of the following symptoms of a heart attack: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back chest pain or chest discomfort that feels like an uncomfortable heavy pressure, squeezing, fullness, or pain pain or discomfort in your arms, back, neck, jaw, or stomach shortness of breath with or without chest discomfort breaking out in a cold sweat nausea or vomiting feeling lightheaded Eletriptan hydrobromide tablets are not for people with risk factors for heart disease unless a heart exam is done and shows no problem. You have a higher risk for heart disease if you: have high blood pressure have high cholesterol levels smoke are overweight have diabetes have a family history of heart disease are a female who has gone through menopause are a male over age 40 Serotonin syndrome. Serotonin syndrome is a serious and life-threatening problem that can happen in people taking eletriptan hydrobromide tablets, especially if eletriptan hydrobromide tablets are taken with anti-depressant medicines called selective serotonin reuptake inhibitors (SSRIs) or serotonin and norepinephrine reuptake inhibitors (SNRIs). Ask your doctor or pharmacist for a list of these medicines if you are not sure. […]
From the patient leaflet: What should I avoid while taking eletriptan hydrobromide tablets?Eletriptan hydrobromide tablets can cause dizziness, weakness, or drowsiness. If you have these symptoms, do not drive a car, use machinery, or do anything where you need to be alert.
From the patient leaflet: How should I store eletriptan hydrobromide tablets?Store eletriptan hydrobromide tablets at room temperature between 68°F to 77°F (20°C to 25°C).
Source: FDA drug label (Eletriptan Hydrobromide), Teva Pharmaceuticals USA, Inc., effective November 27, 2024 (SPL set 62dc12ce-4f19-41c6-9593-3cae29f04af1), via openFDA; the full label on DailyMed
Is there a generic for eletriptan (Relpax)?
The FDA approved the first generic eletriptan on June 16, 2017. 9 generic applications are approved; 7 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale. Drugs@FDA also holds 1 tentative approval: the FDA found the generic approvable, but patents or exclusivity keep it from final approval for now.
FDA's NDC Directory lists eletriptan from 10 labelers under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 2002 earliest approval on file
- 2017 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for eletriptan (Relpax)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $1.75 per Eletriptan hbr 40 mg tablet, down 15% from $2.06 on October 8, 2025. Prices per unit in the table differ many-fold by strength, form and brand, so compare like with like. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Eletriptan hbr 40 mg tablet (generic)
- Relpax 40 mg tablet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Eletriptan hbr 20 mg tablet | Generic | $1.73 per tablet | $51.88 | -13% |
| Eletriptan hbr 40 mg tablet | Generic | $1.75 per tablet | $52.35 | -15% |
| Relpax 20 mg tablet | Brand | $77.37 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $2,321.11 | -0.3% |
| Relpax 40 mg tablet | Brand | $77.05 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $2,311.46 | -0.5% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has eletriptan been recalled?
The FDA's Enforcement Report lists 1 recall naming eletriptan since 2021: 0 Class I (the most serious), 1 Class II, 0 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| March 15, 2021 | Class II | Cardinal Health Inc. | CGMP Deviations: Intermittent exposure to temperature excursion during storage. |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the eletriptan label say about other medicines?
The eletriptan label names 8 other medicines in its interaction, contraindication or warning sections. The labels of 4 other medicines name eletriptan. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Clarithromycin | contraindications | Recent use (i.e., within at least 72 hours) of the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir [see Drug Interactions (7.2) and Clinical Pharmacology ( 12.3 )]. |
| Dihydroergotamine | contraindications | Recent use (i.e., within 24 hours) of another 5-hydroxytryptamine 1 (5-HT 1 ) agonist, ergotamine-containing medication, or ergot-type medication such as dihydroergotamine (DHE) or methysergide [see Drug Interactions ( 7.1 )]. |
| Ergotamine | warnings and precautions | Overuse of acute migraine drugs (e.g. ergotamine, triptans, opioids, or combination of these drugs for 10 or more days per month) may lead to exacerbation of headache (medication overuse headache). |
| Itraconazole | contraindications | Recent use (i.e., within at least 72 hours) of the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir [see Drug Interactions (7.2) and Clinical Pharmacology ( 12.3 )]. |
| Ketoconazole | contraindications | Recent use (i.e., within at least 72 hours) of the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir [see Drug Interactions (7.2) and Clinical Pharmacology ( 12.3 )]. |
| Nefazodone | contraindications | Recent use (i.e., within at least 72 hours) of the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir [see Drug Interactions (7.2) and Clinical Pharmacology ( 12.3 )]. |
| Nelfinavir | contraindications | Recent use (i.e., within at least 72 hours) of the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir [see Drug Interactions (7.2) and Clinical Pharmacology ( 12.3 )]. |
| Ritonavir | contraindications | Recent use (i.e., within at least 72 hours) of the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir [see Drug Interactions (7.2) and Clinical Pharmacology ( 12.3 )]. |
Other labels that name eletriptan
Source: FDA drug label (Eletriptan Hydrobromide), Teva Pharmaceuticals USA, Inc., effective November 27, 2024 (SPL set 62dc12ce-4f19-41c6-9593-3cae29f04af1), via openFDA; the full label on DailyMed
What do FAERS reports show for eletriptan?
The FDA Adverse Event Reporting System holds 6,996 reports that list eletriptan among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 97 are coded as a death and 1,223 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as eletriptan?
12 other medicines are given the same way (oral) and in the same FDA class as eletriptan or labeled mainly for the same use (migraine), the same class first. Migraine lists all 27 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Sumatriptan | Migraine | 22 labelers | $0.302 per tablet 50 mg tablet | No current entry |
| Rizatriptan | Migraine | 25 labelers | $0.335 per tablet 10 mg tablet | No current entry |
| Zolmitriptan | Migraine | 18 labelers | $1.02 per tablet 2.5 mg tablet | No current entry |
| Naratriptan | Migraine | 4 labelers | $1.08 per tablet 2.5 mg tablet | No current entry |
| Almotriptan | Migraine | 3 labelers | $16.86 per tablet 12.5 mg tablet | No current entry |
| Naproxen and sumatriptan | Migraine | 3 labelers | $10.46 per unit 85-500 mg | No current entry |
| Frovatriptan | Migraine | 4 labelers | $2.72 per tablet 2.5 mg tablet | A presentation being discontinued |
| Meloxicam and rizatriptan | Migraine | none listed | $122.64 per tablet 20-10 mg tablet | No current entry |
Every medicine labeled for the same conditions as eletriptan
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does eletriptan compare with medicines for the same use?
3 side-by-side pages set eletriptan beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to eletriptan
- 12 medicines for the same use
- Other triptans
- the pharmacologic class, with prices and generics
- Eletriptan side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other